论文部分内容阅读
目的:观察干扰素在治疗慢性乙型病毒性肝炎中的临床疗效。方法:将治疗组、药物组两组均采用保肝药物治疗,治疗组加用重组基因干扰素α-2b治疗。结果:治疗组与对照组在治疗后的第1、第3、第6个月ALT复常率比较,差异无统计学意义(P>0.05);治疗组HBeAg阴转率、血清转换率,HBV-DNA阴转率均较对照组高,差异均有统计学意义(P<0.05)。结论:应用重组基因干扰素α-2b治疗慢性乙型病毒性肝炎安全可靠,疗效确切。
Objective: To observe the clinical efficacy of interferon in the treatment of chronic hepatitis B virus. Methods: The treatment group and the drug group were treated with hepatoprotective drugs. The treatment group was treated with recombinant interferon alpha-2b. Results: There was no significant difference in the ALT normalization rate between the treatment group and the control group on the 1st, 3rd, and 6th month after treatment (P> 0.05). The HBeAg negative conversion rate, seroconversion rate, -DNA negative conversion rate than the control group, the difference was statistically significant (P <0.05). Conclusion: It is safe and reliable to use recombinant interferon α-2b in the treatment of chronic hepatitis B with definite effect.